Indivior (NASDAQ:INDV) Coverage Initiated at Rodman & Renshaw

Equities researchers at Rodman & Renshaw assumed coverage on shares of Indivior (NASDAQ:INDV) in a research note issued on Tuesday, MarketBeat.com reports. The brokerage set a “buy” rating and a $16.00 price target on the stock. Rodman & Renshaw’s price target points to a potential upside of 31.69% from the company’s previous close.

Several other equities analysts have also recently weighed in on the company. Craig Hallum cut their price objective on Indivior from $20.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, October 11th. Piper Sandler reaffirmed an “overweight” rating and issued a $16.00 price target (up previously from $15.00) on shares of Indivior in a report on Friday, October 25th.

Indivior Stock Performance

NASDAQ INDV opened at $12.15 on Tuesday. Indivior has a twelve month low of $7.33 and a twelve month high of $23.22. The stock has a market capitalization of $1.68 billion, a PE ratio of -303.67 and a beta of 0.74. The stock has a 50-day simple moving average of $11.72 and a 200 day simple moving average of $11.01.

Hedge Funds Weigh In On Indivior

Large investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in Indivior in the 4th quarter valued at approximately $56,000. Stifel Financial Corp bought a new stake in shares of Indivior in the 3rd quarter valued at approximately $100,000. Melqart Asset Management UK Ltd bought a new stake in shares of Indivior in the 3rd quarter valued at approximately $132,000. Jane Street Group LLC bought a new stake in shares of Indivior in the 3rd quarter valued at approximately $180,000. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Indivior in the 3rd quarter valued at approximately $294,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.